• If you are wondering whether Abbott Laboratories at around US$91.13 is starting to look like value or still has more room to fall, the key is to understand what the current price actually reflects.
• The stock has recently pulled back, with a 5.9% decline over the last 7 days, a 13.1% drop over the past month, and returns of 26.6% lower year to date and 27.8% lower over the past year.
• That kind of move often follows changing expectations about growth, risk, or capital allocation. It can prompt investors to reassess what they are prepared to pay for future cash flows. While there has not been a single headline event provided here to explain the shift, the recent price performance itself is an important signal that sentiment and assumptions around the business are being recalibrated.
• On Simply Wall St's 6 point valuation framework, Abbott Laboratories currently scores 5 out of 6. The sections that follow break down how different valuation methods arrive at that view and point toward an even more complete way of thinking about value at the end of the article.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using an appropriate rate. It is essentially asking what those future dollars are worth in current terms.

For Abbott Laboratories, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $7.28b. Analyst estimates and Simply Wall St extrapolations point to Free Cash Flow of around $10.39b by 2028, with further projections running out to 2035, all expressed in US dollars.

When those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $132.34 per share. Compared with the recent share price around $91.13, this implies an intrinsic discount of roughly 31.1%. This indicates that the stock is currently priced below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 31.1%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It links the share price directly to current earnings, which many investors already watch closely, and is widely used across sectors.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty usually points to a lower one.

Abbott Laboratories currently trades on a P/E of about 25.4x. That is very close to the Medical Equipment industry average P/E of 25.1x, and below the broader peer group average of 36.3x. Simply Wall St’s Fair Ratio for Abbott Laboratories is 36.0x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and key risks.

Because the Fair Ratio builds these company specific inputs into a single figure, it can provide a more tailored view than simple peer or industry comparisons. With the current 25.4x P/E sitting below the 36.0x Fair Ratio, the shares appear undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier the article mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a clear story to connect your view of Abbott Laboratories to the numbers you see on screen.

A Narrative is simply your explanation of what you think is happening at a company, which you then tie to explicit assumptions about future revenue, earnings and profit margins, and ultimately to the fair value you think is reasonable.

On Simply Wall St, within the Community page used by millions of investors, Narratives help you link Abbott Laboratories story to a financial forecast. This allows you to compare your fair value to the current share price and decide whether the stock looks expensive or cheap on your terms, without relying only on a single P/E or DCF output.

Those Narratives update automatically as new information such as earnings or news is added. You can see how different views line up, for example one Abbott Laboratories Narrative that arrives at a fair value near US$113.88, and another that lands closer to US$118.64, reflecting different expectations for growth, margins and the P/E that investors might be willing to pay.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.